Stem Cell Treatment For Blindness In India

Clinical trials of the treatment for stargardt s disease a rare incurable eye disease that causes blindness early in adulthood are expected to begin next year british newspaper the times reported.

Stem cell treatment for blindness in india.

Age related macular degeneration amd is the third leading cause of blindness worldwide with almost 1 75 million people in the us this equates to 2 4. Stem cell therapy in india. Stem cell therapy for blindness is now a reality dr virender s sangwan there are several areas in the eye which are being investigated by treatment with stem cells. Retinopathy stem cell treatment in india is considered a befitting procedure that works towards providing optimum results.

Welcome to our website which promises high quality stem cell therapy in india at extremely affordable packages. Stem cell therapy cost in india is significantly economical but the medical services provided by the hospitals are top notch with international medical standards and latest technologies. Preeti dehradoon armd disease. After trying all treatment then i have decided to initiate this stem cell treatment at india s best eye stem cell center because they have given me positive hopes and confident so that i was ready to take this stem cell treatment.

Fair pricing of stem cell treatment in india is also a factor which is giving a new ray of hope to the patients who are in need of stem cell therapy. Breaking research scientists are to use embryonic stem cell therapy to cure blindness in people. In india have a grooming and vibrant regenerative stem cell treatment community built on an approach demands for this specialization. Bone marrow cell transplant we transplant own bone marrow derived mono nuclear cell concentrate which contains growth factors and regenerative cells for repair and regeneration.

It is believed that out of many genes accountable for the normal eye functioning one faulty gene can causes this type of retinal malformation. An emerging stem cell derived treatment designed to preserve and potentially restore vision in people with retinitis pigmentosa rp has demonstrated a favorable safety profile in an ongoing phase i ii clinical trial at the university of california irvine the therapy is being developed by the regenerative medicine company jcyte with trial funding from the california institute for regenerative. It has been suggested that this cell may also be able to act as a stem cell in humans in which case it may provide another source of retinal cells for repair of the retina.